Last reviewed · How we verify

intravenous use of sulodexide followed by oral use

Sun Yat-sen University · FDA-approved active Small molecule Quality 0/100

intravenous use of sulodexide followed by oral use is a Small molecule drug developed by Sun Yat-sen University. It is currently FDA-approved. Also known as: sequential use of sulodexide.

At a glance

Generic nameintravenous use of sulodexide followed by oral use
Also known assequential use of sulodexide
SponsorSun Yat-sen University
ModalitySmall molecule
PhaseFDA-approved

Approved indications

No approved indications tracked.

Common side effects

No common side effects on file.

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about intravenous use of sulodexide followed by oral use

What is intravenous use of sulodexide followed by oral use?

intravenous use of sulodexide followed by oral use is a Small molecule drug developed by Sun Yat-sen University.

Who makes intravenous use of sulodexide followed by oral use?

intravenous use of sulodexide followed by oral use is developed and marketed by Sun Yat-sen University (see full Sun Yat-sen University pipeline at /company/sun-yat-sen-university).

Is intravenous use of sulodexide followed by oral use also known as anything else?

intravenous use of sulodexide followed by oral use is also known as sequential use of sulodexide.

What development phase is intravenous use of sulodexide followed by oral use in?

intravenous use of sulodexide followed by oral use is FDA-approved (marketed).

Related